Emerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer …

Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven precision oncology company, today announced it has scheduled a Type C ...
Seeking Alpha

Lung Cancer Patient in Lantern Pharma’s Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years

DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR ® AI platform, today announces remarkable ...

Biomednewsbreaks - Lantern Pharma (NASDAQ: LTRN) Schedules FDA Type C Meeting For HARMONIC Trial Amendments

Schedules FDA Type C Meeting For HARMONIC Trial Amendments. Lantern Pharma (NASDAQ: LTRN) announced it has scheduled a mid-May 2026 Type C meeting with the U.S. Food and Drug Administration to seek fe ...
Insider Monkey

Lantern Pharma Inc. (LTRN)’s LP-184 Shows 345% Survival Gain in Rare Pediatric Brain Tumor Models

Lantern Pharma Inc. (NASDAQ:LTRN)’s investigational drug LP-184 has achieved a major milestone in the fight against pediatric brain cancer, following independent validation by Johns Hopkins University ...